The PSA Test, Explained Without the Confusion
Key takeaways
- PSA signals that something may be happening, not what.
- Benign conditions commonly raise it; context and trends matter.
- Guidelines centre on shared decision-making, not blanket rules.
- Modern pathways reduced the harms of investigation substantially.
Few blood tests generate more confusion than PSA. Understanding what it can and cannot say turns a fraught topic into an informed decision.
What PSA actually measures
PSA is a protein made by prostate tissue; higher blood levels can signal cancer, but also benign enlargement, inflammation, infection or recent activity affecting the gland. That is the core limitation: PSA detects that something may be happening, not what. Results are interpreted with age, trend over time and follow-up tools, not as a single verdict.
Why guidelines differ
Screening finds some cancers early and saves some lives; it also flags slow-growing cancers that would never have caused harm, historically leading to biopsies and treatments with real side effects. Guidelines therefore emphasise shared decision-making rather than blanket rules, with discussion typically starting around 50, earlier with family history or higher-risk ancestry. Modern pathways, repeat tests, MRI before biopsy, active surveillance, have softened the old downsides considerably.
Having the informed conversation
Useful questions for your doctor: given my age, history and ancestry, what would we do with a high result? What follow-up comes before any biopsy? An informed man choosing screening or declining it are both legitimate outcomes; the goal is a decision made with eyes open rather than by default or by fear.
This article is for general informational purposes only and is not medical advice. Always consult a qualified healthcare professional about your individual situation, and never start or stop a medication without your doctor. See our Medical Disclaimer.